Johan Vansteenkiste

Research interests

Publications

• Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa2002787

• Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1913662

• CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2018 · https://doi.org/10.1200/jco.2018.78.3118

• Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

  New England Journal of Medicine · 2018 · https://doi.org/10.1056/nejmoa1809697

• Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR -Mutated, MET Factor–Dysregulated Non–Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2018 · https://doi.org/10.1200/jco.2018.77.7326

• Phenotype molding of stromal cells in the lung tumor microenvironment

  Nature Medicine · 2018 · https://doi.org/10.1038/s41591-018-0096-5

• Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study

  The Lancet Oncology · 2018 · https://doi.org/10.1016/s1470-2045(18)30673-9

• Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

  The Lancet Oncology · 2018 · https://doi.org/10.1016/s1470-2045(18)30144-x

• Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1713137

• Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2016 · https://doi.org/10.1093/annonc/mdw326

• Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(15)00614-2

• Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)00099-1

• Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2014 · 10.1056/nejmoa1311107

• Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy

  Journal of Clinical Oncology · 2013 · https://doi.org/10.1200/jco.2012.44.3762

• Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First-Line Treatment of Advanced, Nonsquamous Non–Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2012 · https://doi.org/10.1200/jco.2011.39.7646

• Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial

  Journal of Clinical Oncology · 2011 · https://doi.org/10.1200/jco.2010.29.5717

• Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2008 · https://doi.org/10.1200/jco.2007.15.0375

• Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2003 · https://doi.org/10.1200/jco.2003.10.038

Current projects

No projects listed.